<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A real-time polymerase chain reaction assay for quantitation of Epstein-Barr virus (EBV) DNA in serum was developed </plain></SENT>
<SENT sid="1" pm="."><plain>This assay detected EBV DNA in 24 (89%) of 27 sera from patients with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, but only in 9 (18%) of 51 sera from EBV carriers (P &lt; 0.001) and in none of the sera from 32 EBV-seronegative individuals </plain></SENT>
<SENT sid="2" pm="."><plain>EBV DNA levels were higher in sera from <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> (median 8,000, range 1833-150,069 copies/ml) than from carriers (median &lt; 2, range &lt; 2-2980; P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>In sera of 36 children with <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> followed prospectively, EBV DNA levels correlated inversely with the duration of symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>Among 18 children with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> including <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (n = 7), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 6), Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (n = 4), and <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> (n = 1), EBV DNA was detected in serum from those 9 (100%) expressing EBV in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, 3; non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 2; <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo>, 4), the levels peaking at diagnosis and correlating with disease activity </plain></SENT>
<SENT sid="5" pm="."><plain>Quantitation of EBV DNA in serum may offer a simple means of monitoring patients at risk of EBV-associated lymphoproliferation </plain></SENT>
</text></document>